

Sabina Sanghera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1622823/publications.pdf>

Version: 2024-02-01

22
papers

568
citations

933447

10
h-index

752698

20
g-index

23
all docs

23
docs citations

23
times ranked

1527
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. <i>Health Technology Assessment</i> , 2015, 19, 1-118.	2.8	320
2	Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models. <i>BMC Cancer</i> , 2018, 18, 84.	2.6	30
3	The criterion validity of willingness to pay methods: A systematic review and meta-analysis of the evidence. <i>Social Science and Medicine</i> , 2019, 232, 238-261.	3.8	28
4	Adapting the CHEERS Statement for Reporting Cost-Benefit Analysis. <i>Pharmacoeconomics</i> , 2015, 33, 533-534.	3.3	25
5	A pedometer-based walking intervention in 45- to 75-year-olds, with and without practice nurse support: the PACE-UP three-arm cluster RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-274.	2.8	22
6	Levonorgestrel-Releasing Intrauterine System vs. Usual Medical Treatment for Menorrhagia: An Economic Evaluation Alongside a Randomised Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e91891.	2.5	18
7	Measuring Quality-Adjusted Life-Years When Health Fluctuates. <i>Value in Health</i> , 2020, 23, 343-350.	0.3	17
8	ECONOMIC EVALUATIONS AND DIAGNOSTIC TESTING: AN ILLUSTRATIVE CASE STUDY APPROACH. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 53-60.	0.5	13
9	Response process validity of three patient reported outcome measures for people requiring kidney care: a think-aloud study using the EQ-5D-5L, ICECAP-A and ICECAP-O. <i>BMJ Open</i> , 2020, 10, e034569.	1.9	13
10	Cluster randomised controlled trial of a financial incentive for mothers to improve breast feeding in areas with low breastfeeding rates: the NOSH study protocol. <i>BMJ Open</i> , 2016, 6, e010158.	1.9	12
11	Using a Modified Delphi Approach to Gain Consensus on Relevant Comparators in a Cost-Effectiveness Model: Application to Prostate Cancer Screening. <i>Pharmacoeconomics</i> , 2021, 39, 589-600.	3.3	11
12	Pharmaceutical treatments to prevent recurrence of endometriosis following surgery: a model-based economic evaluation. <i>BMJ Open</i> , 2016, 6, e010580.	1.9	10
13	Systematic Review of Cost-Effectiveness Models in Prostate Cancer: Exploring New Developments in Testing and Diagnosis. <i>Value in Health</i> , 2022, 25, 133-146.	0.3	8
14	Challenges in Using Recommended Quality of Life Measures to Assess Fluctuating Health: A Think-Aloud Study to Understand How Recall and Timing of Assessment Influence Patient Responses. <i>Patient</i> , 2022, 15, 445-457.	2.7	8
15	An assessment of economic measures used in menorrhagia: A systematic review. <i>Social Science and Medicine</i> , 2013, 98, 149-153.	3.8	7
16	Short-term and long-term cost-effectiveness of a pedometer-based exercise intervention in primary care: a within-trial analysis and beyond-trial modelling. <i>BMJ Open</i> , 2018, 8, e021978.	1.9	7
17	Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial. <i>BMC Cancer</i> , 2020, 20, 971.	2.6	7
18	The effectiveness and cost-effectiveness of a complex community sport intervention to increase physical activity: an interrupted time series design. <i>BMJ Open</i> , 2018, 8, e024132.	1.9	6

#	ARTICLE	IF	CITATIONS
19	Exploring the Use of Cost-Benefit Analysis to Compare Pharmaceutical Treatments for Menorrhagia. <i>Pharmacoeconomics</i> , 2015, 33, 957-965.	3.3	5
20	Sensitivity to scale of willingness to pay within the context of menorrhagia. <i>Health Expectations</i> , 2017, 20, 232-242.	2.6	1
21	Measuring capability wellbeing in adults at different stages of life for use in economic evaluation of health and care interventions: a qualitative investigation in people requiring kidney care. <i>Quality of Life Research</i> , 2021, 30, 2863-2873.	3.1	0
22	Response to Comment on Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening. <i>Pharmacoeconomics</i> , 2021, 39, 969-970.	3.3	0